Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Microtide Biotechnology an innovative company in the field of in vivo cell therapy.
Microtide Biotechnology is an innovative company established in 2019, specializing in the advanced field of in vivo cell therapy. Headquartered in Shanghai, China, the organization is dedicated to pioneering next-generation solutions for cell-based treatments. Its core mission involves developing therapeutic approaches designed to operate directly within a living organism, aiming for more effective and targeted medical interventions. This focus places Microtide Biotechnology at the forefront of developing novel strategies for cellular medicine, addressing the complexities of delivering and integrating therapeutic cells directly into the body.
Microtide Biotechnology specializes in in vivo cell therapy, concentrating on developing next-generation cell-based treatments that function directly within the body.
Microtide Biotechnology raised over RMB 100 million in funding, with Qiming Venture Partners serving as the lead investor for this round.
Yes, Microtide Biotechnology is also known by the name Weitao Bio.
Microtide Biotechnology specializes in in vivo cell therapy, concentrating on developing next-generation cell-based treatments that function directly within the body.
Microtide Biotechnology raised over RMB 100 million in funding, with Qiming Venture Partners serving as the lead investor for this round.
Yes, Microtide Biotechnology is also known by the name Weitao Bio.
Microtide Biotechnology, also known as Weitao Bio, is a Shanghai-based company founded in 2019 with a specialized focus on in vivo cell therapy. The company is committed to advancing next-generation therapeutic strategies by developing innovative cell-based treatments that can be administered and function directly within a living organism. This approach aims to overcome limitations of traditional ex vivo methods, potentially offering more direct and efficient delivery of cellular therapies.
The company has successfully attracted significant investment to fuel its research and development initiatives. It secured over RMB 100 million in funding, with Qiming Venture Partners leading the investment round. This capital infusion is crucial for accelerating its work in the complex and rapidly evolving domain of in vivo cell therapy, enabling further scientific exploration and technological development.
Microtide Biotechnology originated as a spin-out, indicating its foundation in prior scientific or technological advancements from a larger research or corporate entity. This background suggests a strong base of expertise and a clear trajectory for translating foundational research into practical therapeutic applications. The company leverages its origins to pursue novel approaches in cellular medicine.
Operating from Shanghai, a recognized hub for biotechnology and innovation, Microtide Biotechnology benefits from a dynamic ecosystem. This strategic location provides access to talent, resources, and a supportive environment conducive to developing advanced biotechnological solutions. The company's efforts are directed towards creating impactful in vivo cell therapy solutions for future medical applications, addressing unmet needs in various disease areas.
Microtide Biotechnology's dedication to in vivo cell therapy positions it at the forefront of a promising area of biotechnology. By focusing on direct delivery and function of cells within the body, the company aims to contribute to the evolution of personalized and regenerative medicine. Its work is poised to influence how cellular therapies are conceived and applied in clinical settings.
Microtide Biotechnology most recently raised Series A in February 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 2, 2026 | Series A | — | Apricot Capital, Qiming Venture Partners, Xiamen C&D Corporation | Announced |